Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Agilent's (A) results for the fiscal fourth quarter reflect strong momentum in the pharma and applied markets. Also, robust demand across all end markets in China remained a positive.
By Peter Nurse